Patents by Inventor Ian David Wall

Ian David Wall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10844015
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: November 24, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Etienne Levernier, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Publication number: 20200289464
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 17, 2020
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Simon Christopher Cranko LUCAS, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Publication number: 20200291009
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 17, 2020
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Simon Christopher Cranko LUCAS, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Patent number: 10583112
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 10, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Publication number: 20200009140
    Abstract: The present invention is directed to pyridyl derivatives which are bromodomain inhibitors, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases or conditions
    Type: Application
    Filed: February 27, 2018
    Publication date: January 9, 2020
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Etienne LEVERNIER, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Publication number: 20190381010
    Abstract: The present invention is directed to pyrazole derivatives, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 19, 2019
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Gemma Michele LIWICKI, Simon Christopher Cranko LUCAS, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON
  • Publication number: 20190359572
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: August 8, 2019
    Publication date: November 28, 2019
    Inventors: Stephen John ATKINSON, Helen Elizabeth AYLOTT, Anthony William James COOPER, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Patent number: 10471050
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 12, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10428026
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Publication number: 20190202786
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: May 22, 2017
    Publication date: July 4, 2019
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Etienne LEVERNIER, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Publication number: 20190151279
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: April 5, 2017
    Publication date: May 23, 2019
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Publication number: 20190119248
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: April 5, 2017
    Publication date: April 25, 2019
    Applicant: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Etienne LEVERNIER, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Publication number: 20180280368
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: October 3, 2016
    Publication date: October 4, 2018
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Publication number: 20180282301
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: September 20, 2016
    Publication date: October 4, 2018
    Inventors: Stephen John ATKINSON, Emmanuel Hubert, Lee Andrew HARRISON, Thomas HAYHOW, David HOUSE, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, IAN David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Publication number: 20180258044
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: August 31, 2016
    Publication date: September 13, 2018
    Inventors: Stephen John ATKINSON, Helen Elizabeth AYLOTT, Anthony William James COOPER, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Patent number: 8513248
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 20, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • Patent number: 8222245
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: July 17, 2012
    Assignee: Glaxo Group Limited
    Inventors: Emmanuel Hubert Demont, Jag Paul Heer, John Skidmore, Ian David Wall, Jason Witherington, Thomas Daniel Heightman, David Nigel Hurst, Christopher Norbert Johnson
  • Publication number: 20120172366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Application
    Filed: April 28, 2010
    Publication date: July 5, 2012
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • Publication number: 20100273770
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Application
    Filed: December 19, 2008
    Publication date: October 28, 2010
    Inventors: Jag Paul Heer, Thomas Daniel Heightman, David Nigel Hurst, Christopher Norbert Johnson, John Skidmore, Ian David Wall
  • Publication number: 20100273771
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Application
    Filed: December 19, 2008
    Publication date: October 28, 2010
    Inventors: Emmanuel Hubert Demont, Jag Paul Heer, John Skidmore, Ian David Wall, Jason Witherington, Thomas Daniel Heightman, David Nigel Hurst, Christopher Norbert Johnson